uniQure NV (LTS:0EE0)
$ 43.91 +1.01 (+2.35%) Market Cap: 3.06 Bil Enterprise Value: 2.53 Bil PE Ratio: 0 PB Ratio: 18.78 GF Score: 51/100

Uniqure NV at TD Cowen Healthcare Conference Transcript

Mar 2, 2026 / 03:30 PM GMT
Release Date Price: $10.42 (-34.08%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

QURE.OQ - Uniqure NV
Uniqure NV at TD Cowen Healthcare Conference
Mar 02, 2026 / 03:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for joining us in the room and online, for, TD Cowan's 46th annual healthcare conference. I'm Joeho, one of the senior biotech analysts here on the team at TD Cowan, and it is my pleasure to have with me today CEO of Unicure, Matt Capita.

Thank you for joining us. Obviously a lot to get through, but, I think we'll start the conversation on a good note. What did we see from the phase 3 data? For Huntington's in 130, if you can take us back, obviously, six months-ish, you know how are we seeing on patient benefit versus natural history and kind of what are the highlights of the phase 3 data from your perspective?

--------------------------------------------------------------------------------
Unidentified_2 [2]
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot